In April 2025 federal prosecutors and the DEA announced that a retail pharmacy on Dixwell Avenue in New Haven had entered into a civil settlement agreement and paid $192,000 to resolve allegations that it violated the civil provisions of the Controlled Substances Act.
The settlement resolved allegations that between January 1, 2022, and May 14, 2024, the pharmacy failed to keep complete and accurate records regarding the receipt and dispensing of controlled substances. The government contended the pharmacy failed to perform a biennial inventory, failed to execute a valid power of attorney, and allowed an unauthorized individual to sign DEA Form 222 order forms on at least eight occasions. It also alleged the pharmacy did not retain required copies of order forms, invoices, and other controlled substance records, and did not record certain required information on order forms.
As part of the settlement, the pharmacy agreed to enter into a three-year Memorandum of Agreement with the DEA designed to ensure future compliance with the Controlled Substances Act and its regulations. Officials described accurate recordkeeping as vital to preventing diversion.
The investigation was conducted by the DEA's Office of Diversion Control with assistance from the Connecticut Department of Consumer Protection, Drug Control Division. The civil settlement resolved allegations and is not a finding of liability.